呈交日期： 2025年8月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

Core Viewpoint - Lijun Group's 2025 interim report shows stable revenue performance with a slight decrease in total revenue but an increase in net profit, indicating resilience in its business operations and growth potential in specific segments [1][2]. Revenue Performance - In the first half of 2025, Lijun Group achieved revenue of 6.272 billion yuan, a year-on-year decrease of 0.17%, while net profit attributable to shareholders reached 1.281 billion yuan, a year-on-year increase of 9.40% [1]. - The second quarter revenue was 3.091 billion yuan, reflecting a year-on-year growth of 1.71%, with net profit attributable to shareholders at 644 million yuan, up 14.42% year-on-year [1]. Business Segment Analysis - Chemical preparations generated revenue of 3.270 billion yuan (up 1.43% year-on-year), while traditional Chinese medicine revenue was 799 million yuan (up 7.31% year-on-year). However, raw material drug revenue decreased to 1.662 billion yuan (down 5.65% year-on-year) [2]. - Growth in chemical preparations was driven by gastrointestinal products (1.351 billion yuan, up 3.87%) and psychiatric products (317 million yuan, up 6.89%). The traditional Chinese medicine segment benefited from increased penetration in pharmacy channels [2]. Product Development and Pipeline - Lijun Group has a rich R&D pipeline, with products like Aripiprazole microspheres and progesterone injection approved for market launch. Ongoing clinical trials include an anti-IL-17A/F antibody for psoriasis and a gout medication showing promising results [3]. - The company employs a self-research and business development model to rapidly enhance its product pipeline, with products in the autoimmune and gastrointestinal fields expected to enter a harvest phase soon [3]. Future Outlook - The company maintains a "buy" rating, projecting revenues of 12.343 billion yuan, 12.926 billion yuan, and 13.573 billion yuan for 2025-2027, with respective year-on-year growth rates of 4.50%, 4.72%, and 5.00% [4]. - Net profit forecasts for the same period are 2.272 billion yuan, 2.457 billion yuan, and 2.646 billion yuan, with year-on-year growth rates of 10.23%, 8.16%, and 7.69% [4]. Investment Thesis - Given Lijun Group's strong sales capabilities and its strategy of rapidly supplementing its product pipeline through self-research and business development, the "buy" rating is maintained [5].

Core Insights - Zhuhai's private enterprises are transitioning from "individual efforts" to "collective action" in response to global supply chain restructuring and industrial upgrades [1][3] - The establishment of the Zhuhai Municipal Federation of Industry and Commerce's Modern Industrial System Special Committee aims to create a collaborative development platform covering a "4+3" industrial system [1][2] Group 1: Establishment of Special Committees - Nine specialized committees have been formed, focusing on new generation information technology, new energy, new materials, electronic chemicals, intelligent manufacturing, biomedicine, medical devices, cross-border trade, low-altitude economy, and marine economy [1][2] - Leading companies like Gree Electric Appliances, Livzon Pharmaceutical Group, and SANY Marine Heavy Industry will play significant roles in their respective committees, driving innovation and collaboration within their industries [2] Group 2: Addressing Economic Challenges - The private economy in Zhuhai contributes 91% of the city's business entities and 85% of urban employment, yet faces pressures from global supply chain changes, technological upgrades, and talent shortages [3] - Companies like Guangdong Jianshi Lock have invested heavily in automation, reducing workforce from nearly 4,000 to about 700 while significantly increasing production [3] Group 3: Digital Transformation and Market Adaptation - SANY Marine has initiated a digital transformation strategy focusing on smart manufacturing and operations, which has improved production efficiency and quality [4] - Companies are adapting to international market challenges by establishing overseas production facilities to mitigate tariffs, as seen with Jianshi Lock's operations in Thailand and Peru [4]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年8月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

丽珠医药(01513)发布公告，于2025年8月25日斥资299.92万元回购7.23万股A股股份。 ...

Group 1 - The company, Lijun Pharmaceutical (01513.HK), announced a share buyback on August 25, 2023, spending 2.9992 million yuan to repurchase 72,300 A-shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年8月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

Group 1 - The core viewpoint of the news highlights the recent stock performance and financial metrics of Lizhu Group, indicating a positive trend in stock price and a slight decrease in revenue [1][2] - As of August 25, Lizhu Group's stock price increased by 2.02% to 41.85 CNY per share, with a total market capitalization of 37.837 billion CNY [1] - The company has seen a year-to-date stock price increase of 13.35%, with a 2.45% rise over the last five trading days [1] Group 2 - Lizhu Group's main business segments include chemical preparations (52.14%), raw materials and intermediates (26.49%), traditional Chinese medicine preparations (12.75%), diagnostic reagents and equipment (5.97%), and biological products (1.51%) [2] - For the first half of 2025, Lizhu Group reported operating revenue of 6.272 billion CNY, a slight decrease of 0.17% year-on-year, while net profit attributable to shareholders increased by 9.40% to 1.281 billion CNY [2] - The company has distributed a total of 10.523 billion CNY in dividends since its A-share listing, with 3.721 billion CNY distributed in the last three years [3]

Group 1 - The core viewpoint of the article highlights the growth trends in China's chemical pharmaceutical industry, with a projected production increase in raw chemical drugs by 5.4% in 2025 [1] - According to the National Bureau of Statistics, the production of raw chemical drugs in China reached 333,000 tons in June 2025, reflecting a year-on-year growth of 5.4% [1] - For the first half of 2025, the cumulative production of raw chemical drugs in China was 1.92 million tons, showing a cumulative growth of 4.8% [1] Group 2 - The article lists several publicly listed companies in the pharmaceutical sector, including Heng Rui Medicine, East China Pharmaceutical, and others [1] - It references a report by Zhiyan Consulting that analyzes the supply and demand dynamics of the chemical pharmaceutical industry in China from 2025 to 2031 [1]

Group 1 - The stock price of Lizhu Group is 41.02 yuan, down 0.65% from the previous trading day's closing price [1] - The opening price was 41.35 yuan, with a high of 41.44 yuan and a low of 40.63 yuan, and the trading volume reached 120,447 hands with a transaction amount of 493 million yuan [1] - Lizhu Group operates in the chemical pharmaceutical sector, focusing on the research, production, and sales of pharmaceutical products, including chemical preparations, traditional Chinese medicine preparations, and biological products [1] Group 2 - The latest list of the top ten circulating shareholders shows that the China Europe Medical Health Mixed Fund managed by Ge Lan has become the sixth largest circulating shareholder, holding 5.939 million shares [1] - On August 21, 30 funds participated in a research activity regarding the company, indicating strong interest from institutional investors [1] - Research reports indicate that the company's fundamentals remain stable, with balanced performance across chemical preparations, traditional Chinese medicine, and biological products [1] Group 3 - In terms of capital flow, Lizhu Group saw a net inflow of 44.4728 million yuan from main funds, accounting for 0.19% of the circulating market value [1] - Over the past five days, the cumulative net inflow of main funds was 16.4936 million yuan, representing 0.07% of the circulating market value [1]